Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients

Diabetes, Obesity and Metabolism

Volumn 12, Issue 9, 2010, Pages 752-756

  Chan, D C ^a   Hamilton, S J ^a   Rye, K A ^b,c,d   Chew, G T ^a   Jenkins, A J ^d   Lambert, G ^b,e   Watts, G F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c University of Sydney   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITÉ DE NANTES   (France)

Author keywords

Fenofibrate; PCSK9; Type 2 diabetes; VLDL metabolism

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; ROSUVASTATIN; SIMVASTATIN; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77955046691     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01229.x     Document Type: Article

References (29)

1. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis 2009, 203:1-7.
2. Abifadel M, Varret M, Rabes JP. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
3. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
4. Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 2008, 49:1303-1311.
5. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009, 50:S172-S177.
6. Le May C, Kourimate S, Langhi C. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009, 29:684-690.
7. Lambert G, Jarnoux AL, Pineau T. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 2006, 147:4985-4995.
8. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002, 51:3486-3491.
9. Kissebah AH, Adams PW, Harrigan P, Wynn V. The mechanism of action of clofibrate and tetranicotinoylfructose (Bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia. Eur J Clin Invest 1974, 4:163-174.
10. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
11. Haubenwallner S, Essenburg AD, Barnett BC. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995, 36:2541-2551.
12. Chan DC, Watts GF, Ooi EMM, Ji J, Johnson AG, Barrett PHR. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1831-1837.
13. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008, 49:394-398.
14. Kourimate S, Le May C, Langhi C. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008, 283:9666-9673.
15. Lambert G, Ancellin N, Charlton F. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1038-1045.
16. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
17. Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
18. Chan DC, Lambert G, Barrett PHR, Rye KA, Ooi EMM, Watts GF. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL-apolipoprotein B-100 catabolism? Clin Chem 2009, 55:2049-2052.
19. Mayne J, Dewpura T, Raymond A. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008, 7:22.
20. Troutt JS, Alborn WE, Cao G, Konrad RJ. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010, 51:345-351.
21. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
22. Poirier S, Mayer G, Benjannet S. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and apoER2. J Biol Chem 2008, 283:2363-2372.
23. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun 2008, 375:69-73.
24. Frank-Kamenetsky M, Grefhorst A, Anderson NN. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci 2008, 105:11915-11920.
25. Chan JCY, Piper DE, Cao Q. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci 2009, 106:9820-9825.
26. Hodge AM, Jenkins AJ, English DR, O'Dea K, Giles GG. NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diabetes Res Clin Pract 2009, 83:132-139.
27. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18:1046-1053.
28. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
29. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, (in press).